pt enseval putera megatrading tbk. ended march 3, 2016 … · enseval in brief • established in...
Post on 05-Jun-2019
220 Views
Preview:
TRANSCRIPT
COMPANY UPDATEPT ENSEVAL PUTERA MEGATRADING TBK.
Ended March 3, 2016 (Unaudited)
Passion For Excellence:
Creating ExcellenceThrough Innovation
TABLE OF CONTENT
SECTION 1 ENSEVAL IN BRIEF 3
SECTION 2 BUSINESS OVERVIEW 8
SECTION 3 OPERATIONAL OVERVIEW 20
SECTION 4 FINANCIAL OVERVIEW 23
SECTION 5 2016 OVERVIEW 28
2
ENSEVAL IN BRIEF
• Established in October 1973 with the aim of managing the distribution function because of theseparation of the distribution division from the marketing and production division of PT KalbeFarma;
• On 1 August 1994, the Company listed its shares on the Jakarta Stock Exchange;• The Company focuses its activities on distribution and trading services under 5 divisions :
• Pharmaceutical products sales and distribution, which comprised of patented medicines aswell as generic medicines;
• Consumer products, non prescription medicine and nutrition sales and distribution;• Medical equipment sales and distribution, which include marketing activities;• Raw material sales and distribution, which include veterinary product;• Healthcare services.
Integrated healthcare Distribution and Logistic services company through Service Excellence, Technology Driven and Strong Leadership.
1973 – Incorporationof PT Enseval
1988 – Incorporationof PT Arya GuptaCempaka
1993 – PT Arya GuptaCempaka changed its name toPT Enseval PuteraMegatrading
1994 – PT Enseval PuteraMegatrading Tbk conductedits Initial Public Offering
2003 – Incorporationof PT MilleniaDharma Insani
2007 – Incorporation of PTEnseval Medika Prima andPT Global ChemindoMegatrading
2008 – Incorporation of PTRenalmed Tiara Utama
2011 – The CompanyRight Issue to financeexpansion
2012 – Obtained ISO9001:2008certification
2014 – Incorporation of PT Medika Renal Citraprima.
More than 40 years in business, Enseval constanly makes the best effort to obtain sustainable growth.
ENSEVAL IN BRIEF
ENSEVAL IN BRIEF
• Currently, the Company owns and operates 46 branches and 25 branches under subsidiaries, and 31sales office located on Indonesia achipelago;
• The Company also owns 2 Regional Distribution Center (RDC) located in Jakarta and Surabaya;• For the information technology platform, the Company now is using Oracle E-Business Suite Release 12;• Until the end of Sept 2015, the Company's operation supported by over than 5,700 employees.
Become Market Leader Through high quality of information Technology system and competent human resources.
AWARD & SERTIFICATION UNTIL MARCH 2016
2016 OVERVIEW
• ORACLE - EXA Trend-Setter Award.
• FRONTIER - The Best Building and Managing Corporate Image.– PHARMACEUTICAL DISTRIBUTOR.
– MEDICAL EQUIPMENT DISTRIBUTOR.
• FROST & SULLIVAN - Indonesia Pharmaceutical Distributor of the year.
• Department of Animal Husbandry in East Java province - the best distributor of veterinary drug.
• HERMINA HOSPITAL GROUP - The Best Pharmaceutical Distributor.
• BETHESDA HOSPITAL YOGYAKARTA - The Best Pharmaceutical Distributor.
• NIVEA - The Best Weighted Distributor.
• Rekor Bisnis Indonesia - Pharmaceutical Distributor with the Most Outlet Coverage.
• The Most Powerful Distribution Performance– EXTRA JOSS
– KOMIX
• AZ/NZS ISO 9001:2008 Certified
• BS OHSAS 18001:2007 Certified
• Good Distribution Practices Certified (GDP)
• Cara Distribusi Obat yang Baik (CDOB Certified)
AWARD & SERTIFICATION UNTIL MARCH 2016
2016 OVERVIEW
*Description of net sales per products as describe below :
BUSINESS OVERVIEW
NET SALES PER PRODUCTS UNTIL MARCH 31, 2016
Products Portfolio Net Sales (Rp)Contribution to Total Net Sales
Consumer Products 1.939.095.368.638 43,97%
Prescription Medicines 1.242.248.249.055 28,17%
Non Prescription Medicines 686.329.327.954 15,56%
Raw Materials 346.713.262.361 7,86%
Medical Equipment 185.468.618.715 4,21%
Veterinary Products 8.131.285.730 0,18%
Health Care Services 1.618.674.170 0,04%
Total : 4.409.604.786.623 100%
BUSINESS OVERVIEW
DESCRIPTION OF NET SALES PER PRODUCTS AND THE CONTRIBUTION
43,97%28,17%
15,56%
7,86%
4,21% 0,18% 0,04%Consumer Products
Prescription Medicines
Non Prescription Medicines
Raw Materials
Medical Equipment
Veterinary Products
Health Care Services
Net SalesMarch 2016
Rp4,409.60 billion
*Growth of net sales per products as describe below :
BUSINESS OVERVIEW
ALL BUSINESS LINE OF THE COMPANY WERE GREW SIGNIFICANTLY
Products PortfolioNet Sales March 2015
(Rp)Net Sales March 2016
(Rp)Growth %
Consumer Products 1.704.266.238.982 1.939.095.368.638 13,78
Prescription Medicines 1.184.947.877.428 1.242.248.249.055 4,84
Non Prescription Medicines 697.104.357.456 686.329.327.954 (1,55)
Raw Materials 348.126.299.381 346.713.262.361 (0,41)
Medical Equipment 127.207.289.021 185.468.618.715 45,80
Veterinary Products 12.022.562.620 8.131.285.730 (32,37)
Health Care Services 1.451.445.616 1.618.674.170 11,52
Total : 4.075.126.070.504 4.409.604.786.623 8,21
Total NetSales
ConsumerProducts
PrescriptionMedicines
NonPrescriptionMedicines
Raw Materials MedicalDevices
VeterinaryProducts
Health CareServices
2015 2016
4.84 %(1.55) %
(0.41) %45.80 %
BUSINESS OVERVIEW
GROWTH OF NET SALES 2015 VS 2016
8.21 %
(32.37) %11.52 %
13.78 %
RDC JAKARTARDC SURABAYA46 BRANCH25 BRANCH under subsidiaries (TSJ)29 SALES OFFICE
BUSINESS OVERVIEWNATIONAL COVERAGE 71 FULL SERVICES BRANCHES & MORE THAN 200,000 DIRECT OUTLET COVERAGE
Type of outlet coveraged by the company’s distribution
Covers all trade channels in the market :
BUSINESS OVERVIEW
MORE THAN 200,000 DIRECT OUTLET COVERAGE
General / Traditional Trade Channel
• Wholesalers
• Retailers
• Provision Stores
• Convenience Stores
• Food & Beverage
• Store - Fruit Shops
• Cosmetic Stores
• etc
Modern Trade Channel
• Hypermarkets
• Supermarkets
• Mini Markets
• Departement Stores
• etc
Pharmaceutical Trade Channel
• Pharmacies
• Drugstores
• Hospitals
• Labs – Clinics
• Institutions
• etc
2016 OVERVIEW
SALES CONTRIBUTION BY CHANNEL (MARCH 2015 VS MARCH 2016)
43,30%
35,83%
20,88%
2016
Pharmaceutical Trade General Trade
Modern Trade
42,38%
34,59%
23,03%
2015
Pharmaceutical Trade General Trade
Modern Trade
2016 OVERVIEW
SALES CONTRIBUTION BY PRINCIPAL (MARCH 2015 VS MARCH 2016)
21%
79%
2015
External Principal Internal Principal
19%
81%
2016
External Principal Internal Principal
BUSINESS OVERVIEW
200,000+ DIRECT OUTLET COVERAGE
Pharmacy; 11.571
Hospital; 1.614
Drugstore; 4.485
Wholesaler; 2.260
Hypermarket, 178
Supermarket; 1.179
Minimarket; 3.115
Provision Store; 162.000
F&B Stores; 15.000
Cosmetics; 1.750
Others; 9.800
Covers all trade channels in the market:
- General / Traditional Trade Channel: Wholesalers, Retailers, Provision Stores, Convenience Stores, Food & Beverage Stores, Fruit Shops, Cosmetics Stores, etc
- Modern Trade Channel: Hypermarkets, Supermarkets, Mini Markets, Department Stores, etc
- Ethical Trade Channel: Pharmacies, Drugstores, Hospitals, Labs - Clinics, Institutions, etc
OPERATIONAL OVERVIEW
Mobile application (Tablet Computer & PDA)
- Supervisor: Team Performance Analysis.
- Salesman & Deliveryman: Faster Order Taking & Faster Information Process.
Global Information System (GIS)
- Application for more in depth sales and territory mapping.
Supported by Enseval Customer Care (ECC) – HOTLINE 1500095
In Branches Order Management, Complaint Handling, Basic Product Information.
Customers also can reach Enseval office via Phone, Fax & Email for easy customer ordering.
IT INFRASTRUCTURE
OPERATIONAL OVERVIEW
Centralized IT system using Oracle E-Business Solutions• Integrated & Real Time system
Use the best world-class ERP system by Oracle Complete Oracle E-Business SuiteOracle Warehouse Management System (WMS)Advance Supply Chain Planning (ASCP) and Oracle Demantra
Tablet Computer & PDA system E-Mobile ®2,300+ PDA used by Supervisors, Salesmen, Deliverymen, & Collectors Menu: Distribution Plan, Distribution Achievement, Overdue, etc
Provide data security for antivirus by Trend Micro and Sonic Wall
IT INFRASTRUCTURE
OPERATIONAL OVERVIEW
• ENI (Enseval Net Info) • Web based application
• Sales (hourly updated) & Stock (D-1)
• EXI (Enseval Xpress Info)• SMS based application
• Sales & Stock Report
• ERI (Enseval Raw Data Info)• Raw Data format, distribution and logistics information activities
• ENO (Enseval NET Order)
• Online order with business-to-business system
For Principal
For Customer
COMPREHENSIVE BUSINESS ACCESS
FINANCIAL OVERVIEW
NET SALES GROWTH
4.075,13 3.618,914.409,60 3.895,38
2015 2016
88.80%88.34%
(0.47)%
8.21%
0.58%
: Net Sales in Rp/billion : COGS in Rp/billion
: Net Sales in Rp/billion : COGS in Rp/billion
: COGS Margin
Net Sales COGS
March 31, 2015 (Unaudited)
March 31, 2016 (Unaudited)
March 31, 2015 (Unaudited)
March 31, 2016 (Unaudited)
456,22
514,23
FINANCIAL OVERVIEW
EXPENSE RATIO
12.72%
March 31, 2015 (Unaudited)
March 31, 2016 (Unaudited)
Gross Profit
Gross Profit Margin
Gross Profit (Rp/Billion)
11.20%11.66%0.47%
335,35
370,79
10.57%
March 31, 2015 (Unaudited)
March 31, 2016 (Unaudited)
Operational Expense
Operational Expense Margin
Operational Expense (Rp/Billion)
8.23%8.41%0.18%
FINANCIAL OVERVIEW
PROFIT GROWTH (MARCH 2015 VS MARCH 2016)
120,87 130,6395,45
143,43 170,92123,22
18.66% 30.84%29.09%
Operating Profit Margin Income Before Tax Expense Margin
Income For The Year Margin
March 31, 2015 (Unaudited)
March 31, 2016 (Unaudited)
March 31, 2015 (Unaudited)
March 31, 2016 (Unaudited)
March 31, 2015 (Unaudited)
March 31, 2016 (Unaudited)
2.97%3.25%0.29%
Operating Profit(Rp/Billion)
Income Before Tax Expense (Rp/Billion)
Operating Profit Income Before Tax Expense Income For The Year
3.21% 3.88%0.67%
2.34%2.79%0.45%
FINANCIAL OVERVIEW
FINANCIAL POSITION (DEC 2015 VS MARCH 2016)
6.747,94
2.677,694.070,25
6.852,57
2.654,264.198,32
1.55%
(0.88)%
3.15%
Dec 31, 2015 (Audited)
March 31, 2016 (Unaudited)
Total Assets (Rp/Billion) Total Liabilities (Rp/Billion)
Dec 31, 2015 (Audited)
March 31, 2016 (Unaudited)
Dec 31, 2015 (Audited)
March 31, 2016 (Unaudited)
WAREHOUSE MANAGEMENT SYSTEM-Oracle-based WMS
-Manage stock from
inbound-outbound, by location, SKU, Batch Number, Expiry Date.
-Bar-coding system with mobile bar-code reader to eliminate duplication & increase accurate operation.
33
COLD CHAIN MANAGEMENT-Enseval has implemented and Standardized Cold Chain Management in it’s RDC, Branch Warehouse, and Transportation according to ISO 9001:2008.
-Cold Chain Management is performed with close control
-All activities is always recorded and stored properly
Cold Chain Handling in Enseval Delivery with Temperature Controlled Transportation
Temperature MonitoringDocument
34
STRATEGIC VALUE TO BUSINESS PARTNERS• Strong product portfolio.
• Sustainable business growth.
• Supported by 2 RDC, 46 branches, 31 Sales Office, & 200,000+ direct coverage outlets.
Market Leading Position in Indonesia
• 40+ years of strategic expertise in distribution and logistics service.
• Strong and good relationship with all business players : Principals & Outlets.
• Having in aggregate over 100 years of experience senior management team and supported by more than 5,700 employees.
Reliable Partner to Grow
• Public listed company with professional management that treats all business partners equally with the utmost transparency and accountability.
• Independent business entity with neutrality to ensure fairness to all stakeholders.Transparency and Neutrality
• Robust balance sheet figures.
• Solid financial performance.Strong Financial Track Record
• Commitment to assist & support Principal to achieve it’s goals.
• Implementation of Continuous Improvement (CONIM) in all business aspects by Enseval’s employees in every level.
Enseval’s Commitment Towards Improvement
36
FORWARD LOOKING STATEMENTThis presentation has been prepared for informational purposes only by PT Enseval Putera Megatrading Tbk. ("Enseval" or the "Company")
This presentation has been prepared solely for use in connection with the release 0f 30 September 2015 unaudited results of the Company. The informationcontained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and noreliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company orany of their respective affiliates, and their respective commissioners, directors and employees, advisors or representative shall have any liability whatsoever (innegligence or otherwise) for any loss however arising from any use of this presentation or its contents or otherwise arising in connection with the presentation.Any decision to purchase or subscribe for securities of the Company should not be made on the basis of the information contained in this presentation.The presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or anexemption from registration.This presentation and its contents are confidential unless they are become generally avaiable as public information in accordance with prevailing lawsregulations (other than as a result of a disclosure by you) and must not be distributed, published or reproduced (in whole or in part) or disclosed by receipentsto any other person. This presentation does not constitute a recommendation regarding the securities of the Company.This presentation, including the information and opinions contained herein, is provided as the date of this presentation and is subject to change without notice,including change as a result of the issuance of 30 September 2015 unaudited results of the Company.This presentation includes "forward-looking statements". These statements contain the words "anticipate", "believe", "intend", "estimate", "expect" and wordsof similiar meaning. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding theCompany's financial position, business strategy, plans and objectives of management for future operations (including development plans, objectives relating tothe Company's products and services and anticipated product launches) are forward-looking statements. Such forward-looking statements are based onnumerous assumptions regarding the Company's present and future business strategies and the environment in which of the Company will operate in thefuture. These forward-looking statements speak only ast the date of this presentation. The Company expressly disclaims any obligation or reflection of anychange in the Company's expectations with regard thereto, or any change in events, conditions or circumtances on which any statements is based.Market data and certain industry forecast used in this presentation were obtained from market research, publicity avaiable information and industrypublications which have not been independently verified, and no presentation is made as to the accuracy of such information.
37
top related